Adaptable RNA-based antibody platform for protection against contemporary/emerging human enteroviruses

Ended Definitive Contract Awarded

Contract number
75N93022C00017
Awardee
Awarding agency
Obligated
$1,499,422

Award facts

Contract value 100% obligated
$1,499,422.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541714 Research and Development in Biotechnology (except Nanobiotechnology)
PSC
AN12 Health R&D Services; Health Care Services; Applied Research
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Firm Fixed Price
Place of performance
Seattle, WA 98102, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.5 million firm fixed price definitive contract to HDT Bio Corp. to develop an adaptable RNA-based antibody platform for protection against contemporary and emerging human enteroviruses. The three year contract will support HDT Bio Corp.'s work through June 2025 to create a platform that utilizes RNA-based antibodies to provide protection against various enteroviruses.

Quick answers

Who was awarded contract 75N93022C00017?

75N93022C00017 was awarded to HDT Bio Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2022.

How much is contract 75N93022C00017 worth?

The government has obligated $1,499,422 on 75N93022C00017.

Was contract 75N93022C00017 competed?

The extent of competition for 75N93022C00017 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award